ArticleEuropean journal of cancer (Oxford, England : 1990)2023
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Article in European journal of cancer (Oxford, England : 1990), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis.Breast cancer research and treatment · 2024Pooled it
- Quality of life issues in patients with ductal carcinoma in situ: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia.Cancer prevention research (Philadelphia, Pa.) · 2026Observational
- Development of a Nomogram-Based Clinical Estimation Model for Pathological Upstaging in Patients With Preoperative Ductal Carcinoma In Situ.The Kaohsiung journal of medical sciences · 2026Article
- Prognostic Implications of Calcification and Surgery Type by Estrogen Receptor and HER2 Status in Ductal CarcinomaJournal of breast cancer · 2026Article
- Patient Preferences and Treatment Decision Drivers in IDH-Mutant Grade 2 Glioma: An International Discrete Choice Experiment.The patient · 2026Article
- High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities.Nature communications · 2026Article
- Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.NPJ breast cancer · 2026Article
- Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.Annals of surgical oncology · 2026Article
- Trends in Nonsurgical Management for Low-Risk, Hormone Receptor-Positive Ductal Carcinoma In Situ.JAMA network open · 2026Article
- Invasion prediction with artificial intelligence in ductal carcinoma in situ (DCIS) patients: a proof-of-concept study.BMC surgery · 2025Article
- Watchful waiting for ductal carcinoma in situ: are we ready to step back?European radiology · 2025Article
- Is axillary surgery still justified in DCIS diagnosed via vacuum-assisted biopsy?World journal of surgical oncology · 2025Article
- Mammography screening and incidence of ductal carcinoma in situ of the breast in Italy: an age-period-cohort analysis.International journal of epidemiology · 2025Article
- Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features.EBioMedicine · 2025Article
- The natural history of ductal carcinoma in situ: development, validation, and estimated outcomes of the SimDCIS model.Breast cancer research and treatment · 2025Article
- Lumpectomy surgery for large ductal carcinoma in situ.Breast cancer research and treatment · 2025Article
- COMETgazing - interesting insights, lessons for clinical practice and a call for more precision using the biomarkerSCOPE.Oncotarget · 2025Article
- Risk perception of patients with ductal carcinomaHistology and histopathology · 2025Review
- A Personalized, Risk-Based Approach to Active Surveillance for Prostate Cancer with Takeaways from Broader Oncology Practices: A Mixed Methods Review.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuctal carcinoma in situ (DCIS) can progress to invasive breast cancer (IBC), but most DCIS lesions remain indolent. However, guidelines recommend surgery, often supplemented by radiotherapy. This implies overtreatment of indolent DCIS. The non-randomised patient preference LORD-trial tests whether active surveillance (AS) for low-risk DCIS is safe, by giving women with low-risk DCIS a choice between AS and conventional treatment (CT). Here, we aim to describe how participants are distributed among both trial arms, identify their motives for their preference, and assess factors associated with their choice.
methodsData were extracted from baseline questionnaires. Descriptive statistics were used to assess the distribution and characteristics of participants; thematic analyses to extract self-reported reasons for the choice of trial arm, and multivariable logistic regression analyses to investigate associations between patient characteristics and chosen trial arm.
resultsOf 377 women included, 76% chose AS and 24% CT. Most frequently cited reasons for AS were "treatment is not (yet) necessary" (59%) and trust in the AS-plan (39%). Reasons for CT were cancer worry (51%) and perceived certainty (29%). Women opting for AS more often had lower educational levels (OR 0.45; 95% confidence interval [CI], 0.22-0.93) and more often reported experiencing shared decision making (OR 2.71; 95% CI, 1.37-5.37) than women choosing CT.
conclusionThe LORD-trial is the first to offer women with low-risk DCIS a choice between CT and AS. Most women opted for AS and reported high levels of trust in the safety of AS. Their preferences highlight the necessity to establish the safety of AS for low-risk DCIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.